Familial apolipoprotein E deficiency

The Journal of Clinical Investigation
E J SchaeferH B Brewer

Abstract

A unique kindred with premature cardiovascular disease, tubo-eruptive xanthomas, and type III hyperlipoproteinemia (HLP) associated with familial apolipoprotein (apo) E deficiency was examined. Homozygotes (n = 4) had marked increases in cholesterol-rich very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL), which could be effectively lowered with diet and medication (niacin, clofibrate). Homozygotes had only trace amounts of plasma apoE, and accumulations of apoB-48 and apoA-IV in VLDL, IDL, and low density lipoproteins. Radioiodinated VLDL apoB and apoE kinetic studies revealed that the homozygous proband had markedly retarded fractional catabolism of VLDL apoB-100, apoB-48 and plasma apoE, as well as an extremely low apoE synthesis rate as compared to normals. Obligate heterozygotes (n = 10) generally had normal plasma lipids and mean plasma apoE concentrations that were 42% of normal. The data indicate that homozygous familial apoE deficiency is a cause of type III HLP, is associated with markedly decreased apoE production, and that apoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents.

Associated Clinical Trials

References

Aug 19, 1978·Lancet·E J SchaeferW C Blackwelder
Nov 1, 1977·Annals of Internal Medicine·R S KushwahaJ J Albers
Jan 30, 1978·Biochemical and Biophysical Research Communications·E J SchaeferH B Brewer
Oct 15, 1985·Clinica Chimica Acta; International Journal of Clinical Chemistry·P W WilsonH B Brewer
May 16, 1985·The New England Journal of Medicine·E J Schaefer, R I Levy
Aug 1, 1972·Annals of Internal Medicine
Jan 26, 1967·The New England Journal of Medicine·D S FredricksonR S Lees
Nov 1, 1981·The Journal of Clinical Investigation·R W MahleyK H Weisgraber
Aug 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·S C RallR W Mahley
Aug 1, 1983·The Journal of Clinical Endocrinology and Metabolism·E J SchaeferR I Levy
Jul 1, 1984·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·E J Schaefer
Nov 1, 1983·The Journal of Clinical Endocrinology and Metabolism·R E GreggH B Brewer
Mar 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·A F StalenhoefR J Havel
Jan 1, 1984·Human Genetics·G UtermannA Steinmetz
Jan 1, 1982·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·E J SchaeferH B Brewer
Jul 1, 1983·The Journal of Clinical Investigation·R J HavelT Bersot
Jan 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·F M Van't HooftR J Havel
Jun 24, 1982·The New England Journal of Medicine·R A NorumP Alaupovic
Aug 1, 1982·The Journal of Clinical Investigation·G GhiselliH B Brewer
Sep 24, 1981·Biochimica Et Biophysica Acta·P J BlancheA V Nichols
Dec 1, 1980·The Journal of Clinical Investigation·C B BlumR Sciacca

❮ Previous
Next ❯

Citations

Apr 15, 1983·Klinische Wochenschrift·N B Myant
Aug 15, 1988·Klinische Wochenschrift·T DemantC J Packard
Jan 1, 1997·International Journal of Clinical & Laboratory Research·D J Rader
Apr 14, 2005·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Kirsty GreenowDipak P Ramji
Dec 21, 2000·Current Atherosclerosis Reports·P Duriez, J C Fruchart
Dec 21, 2000·Current Atherosclerosis Reports·D J Rader, U J Tietge
Sep 15, 1994·Biochimica Et Biophysica Acta·J Lopez-MirandaJ M Ordovas
Mar 29, 1996·Clinica Chimica Acta; International Journal of Clinical Chemistry·T TeramotoM Yamanaka
Aug 1, 1994·Atherosclerosis·E J SchaeferP W Wilson
Jul 1, 1996·Atherosclerosis·J Davignon, J S Cohn
Jul 1, 1992·Trends in Cardiovascular Medicine·J Genest
Jul 1, 1993·Trends in Cardiovascular Medicine·L Stoltzfus, E M Rubin
Oct 8, 1999·Clinica Chimica Acta; International Journal of Clinical Chemistry·J DavignonL Bernier
Feb 5, 2000·Atherosclerosis·I A LarsonE J Schaefer
Aug 1, 1987·Baillière's Clinical Endocrinology and Metabolism·R Fears
Oct 1, 1995·Baillière's Clinical Endocrinology and Metabolism·R KirchmairJ R Patsch
Jan 11, 2001·Trends in Cardiovascular Medicine·S FazioL L Swift
May 1, 2007·The Proceedings of the Nutrition Society·A M MinihaneG Rimbach
Sep 16, 2010·Nature Reviews. Neurology·Catrina Sims-RobinsonEva L Feldman
Mar 5, 2011·The Journal of Biological Chemistry·Violeta Georgeta TruscaAnca Violeta Gafencu
May 27, 1999·The Proceedings of the Nutrition Society·J M Ordovas
Sep 1, 1996·The Journal of Experimental Medicine·P SinnisV Nussenzweig
Aug 20, 2010·Human Molecular Genetics·Jonathan RiosJonathan C Cohen
Jul 1, 1997·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·D T LaskowitzD S Warner
Mar 17, 2004·Current Opinion in Lipidology·Vassilis I ZannisDimitris Kardassis
Aug 5, 2010·Current Opinion in Lipidology·Jacob Fog Bentzon, Erling Falk
Jun 11, 1992·Journal of Internal Medicine·S C Rall, R W Mahley
Dec 1, 1996·Journal of Clinical Pathology·G Feussner
Nov 16, 2010·Journal of Biomedicine & Biotechnology·Andrew R Bond, Christopher L Jackson
Sep 26, 2013·Evidence-based Complementary and Alternative Medicine : ECAM·Jung Joo YoonHo Sub Lee
Dec 20, 2000·The Journal of Clinical Investigation·M M VéniantS G Young

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.